Regeneron (REGN) Moves Higher on Strong EYLEA FY12 Sales Outlook, Q4 Numbers
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $834.04 +0.90%
Financial Fact:
Loss from operations: 362.8M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Loss from operations: 362.8M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Regeneron Pharma (Nasdaq: REGN) shares are strongly higher Monday following its fourth-quarter report, but more importantly its outlook.
Regeneron said it now sees fiscal 2012 EYLEA sales in the US of $250 million to $300 million.
Otherwise, fourth-quarter adjusted loss came in at 27 cents per share, beating expectations calling for loss of 60 cents per share.
Shares are up about 12 percent early Monday morning.
Regeneron said it now sees fiscal 2012 EYLEA sales in the US of $250 million to $300 million.
Otherwise, fourth-quarter adjusted loss came in at 27 cents per share, beating expectations calling for loss of 60 cents per share.
Shares are up about 12 percent early Monday morning.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial i
- Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Guidance, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
